Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Accured Expenses: 2018-2023

Historic Change in Accured Expenses for Autolus Therapeutics (AUTL) over the last 5 years, with Sep 2023 value amounting to $31.4 million.

  • Autolus Therapeutics' Change in Accured Expenses rose 722.75% to $31.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $137.6 million, marking a year-over-year increase of 126.57%. This contributed to the annual value of $11.0 million for FY2018, which is 913.42% up from last year.
  • According to the latest figures from Q3 2023, Autolus Therapeutics' Change in Accured Expenses is $31.4 million, which was up 1.40% from $31.0 million recorded in Q2 2023.
  • Autolus Therapeutics' Change in Accured Expenses' 5-year high stood at $40.8 million during Q4 2022, with a 5-year trough of -$27.4 million in Q2 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $28.6 million (2021), whereas its average is $17.9 million.
  • In the last 5 years, Autolus Therapeutics' Change in Accured Expenses plummeted by 220.57% in 2021 and then skyrocketed by 1,723.44% in 2023.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Change in Accured Expenses stood at $15.5 million in 2019, then spiked by 63.37% to $25.4 million in 2020, then grew by 12.73% to $23.7 million in 2021, then skyrocketed by 72.38% to $40.8 million in 2022, then soared by 722.75% to $31.4 million in 2023.
  • Its last three reported values are $31.4 million in Q3 2023, $31.0 million for Q2 2023, and $34.5 million during Q1 2023.